Evidence map›Paper›PMID 40142695›Full record

ArticleJournal of clinical medicine2025

Comparative Analysis of Neuropsychiatric Adverse Reactions Associated with Remdesivir and Nirmatrelvir/Ritonavir in COVID-19 Treatment: Insights from EudraVigilance Data.

Aliteia-Maria Pacnejer, Mihaela Cristina Negru, Anca Maria Arseniu, Cristina Trandafirescu, Cristian Oancea, Felicia Gabriela Gligor, Claudiu Morgovan, Anca Butuca, Cristina Adriana Dehelean

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aliteia-Maria PacnejerDepartment of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania.
Mihaela Cristina NegruDepartment of ENT, "Victor Babeș" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania.ORCID 0000-0002-3002-7656
Anca Maria ArseniuPreclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.ORCID 0000-0001-9801-0060
Cristina TrandafirescuDiscipline of Pharmaceutical Chemistry, Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania.
Cristian OanceaDepartment of Pulmonology, Center for Research and Innovation in Personalized Medicine of Respiratory Diseases, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Felicia Gabriela GligorPreclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.ORCID 0000-0003-3167-9864
Claudiu MorgovanPreclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.ORCID 0000-0003-2730-8729
Anca ButucaPreclinical Department, Faculty of Medicine, "Lucian Blaga" University of Sibiu, 550169 Sibiu, Romania.ORCID 0000-0003-1540-641X
Cristina Adriana DeheleanDepartment of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timișoara, Romania.

Funding

Victor Babeș University of Medicine and Pharmacy Timișoara
6 · The paper itself

Abstract

Remdesivir (RDV) and nirmatrelvir/ritonavir (NMVr) are among the most widely used antivirals in the treatment of COVID-19, aiming to reduce disease severity and progression. Adverse neuropsychiatric effects, such as anxiety, sleep disturbances, and movement disorders, have emerged as significant concerns associated with these treatments. To better understand the safety profiles of RDV and NMVr, this study performs a pharmacovigilance analysis of individual case safety reports (ICSRs) from the EudraVigilance (EV) database.

Indexed as

COVID-19EudraVigilanceneuropsychiatric adverse effectsnirmatrelvir/ritonavirpharmacovigilanceremdesivir

Identifiers

PMID40142695
PMCPMC11942844

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.